Letermovir Side Effects
Medically reviewed by Drugs.com. Last updated on Dec 14, 2020.
For the Consumer
Applies to letermovir: oral tablet
Other dosage forms:
Side effects requiring immediate medical attention
Along with its needed effects, letermovir may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking letermovir:
- Bloating or swelling of the face, arms, hands, lower legs, or feet
- rapid weight gain
- tingling of the hands or feet
- unusual weight gain or loss
Side effects not requiring immediate medical attention
Some side effects of letermovir may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
For Healthcare Professionals
Applies to letermovir: intravenous solution, oral tablet
Side effects included those reported during treatment with study medication or within 2 weeks of study medication completion/discontinuation; the time for reporting side effects and laboratory abnormalities averaged about 22% longer with this drug compared to with placebo. The side effects most commonly reported included nausea, diarrhea, vomiting, peripheral edema, cough, headache, fatigue, and abdominal pain.[Ref]
Decreased hemoglobin (less than 6.5 g/dL: 2%; 6.5 to less than 8 g/dL: 14%; 8 to less than 9.5 g/dL: 41%), platelets (less than 25,000 cells/mcL: 27%; 25,000 to less than 50,000 cells/mcL: 17%; 50,000 to less than 100,000 cells/mcL: 20%), and absolute neutrophil count (less than 500 cells/mcL: 19%; 500 to less than 750 cells/mcL: 4%; 750 to less than 1000 cells/mcL: 8%) were reported during therapy or within 2 weeks of stopping therapy.
Very common (10% or more): Decreased hemoglobin (up to 41%), decreased platelets (up to 27%), decreased absolute neutrophil count (up to 19%)
Very common (10% or more): Nausea (27%), diarrhea (26%), vomiting (19%), abdominal pain (12%)
Very common (10% or more): Increased serum creatinine (up to 17%)
Increased serum creatinine (greater than 2.5 mg/dL: 2%; greater than 1.5 to 2.5 mg/dL: 17%) was reported during therapy or within 2 weeks of stopping therapy.
Very common (10% or more): Peripheral edema (14%), fatigue (13%)
Very common (10% or more): Headache (14%)
Uncommon (0.1% to 1%): Dysgeusia, vertigo
Very common (10% or more): Cough (14%)
Frequency not reported: Dyspnea
The cardiac side effect rate was higher in patients using this drug (13%) compared to those using placebo (6%). Tachycardia (4% [compared to 2% with placebo]) and atrial fibrillation (3% [compared to 1% with placebo]) were the most commonly reported cardiac side effects. Most cardiac side effects were reported as mild or moderate in severity.
Common (1% to 10%): Tachycardia, atrial fibrillation
Uncommon (0.1% to 1%): Hypersensitivity reaction
After switching from the oral formulation, hypersensitivity reaction (associated with moderate dyspnea) was reported in 1 patient after the first IV infusion; as a result, treatment was discontinued.
Uncommon (0.1% to 1%): Increased ALT, increased AST
Uncommon (0.1% to 1%): Decreased appetite
Uncommon (0.1% to 1%): Muscle spasms
More about letermovir
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- En Español
- 1 Review
- Drug class: miscellaneous antivirals
- Patient Information
- Letermovir (Advanced Reading)
- Letermovir Intravenous (Advanced Reading)
- Letermovir Tablets
- Letermovir Injection
- Other brands
Related treatment guides
1. EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."
2. Cerner Multum, Inc. "Australian Product Information." O 0
3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
4. "Product Information. Prevymis (letermovir)." Merck & Company Inc, Whitehouse Station, NJ.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.